Correlation Between Arrowhead Pharmaceuticals and Crispr Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Arrowhead Pharmaceuticals and Crispr Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Arrowhead Pharmaceuticals and Crispr Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Arrowhead Pharmaceuticals and Crispr Therapeutics AG, you can compare the effects of market volatilities on Arrowhead Pharmaceuticals and Crispr Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Arrowhead Pharmaceuticals with a short position of Crispr Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Arrowhead Pharmaceuticals and Crispr Therapeutics.

Diversification Opportunities for Arrowhead Pharmaceuticals and Crispr Therapeutics

0.33
  Correlation Coefficient

Weak diversification

The 3 months correlation between Arrowhead and Crispr is 0.33. Overlapping area represents the amount of risk that can be diversified away by holding Arrowhead Pharmaceuticals and Crispr Therapeutics AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Crispr Therapeutics and Arrowhead Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Arrowhead Pharmaceuticals are associated (or correlated) with Crispr Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Crispr Therapeutics has no effect on the direction of Arrowhead Pharmaceuticals i.e., Arrowhead Pharmaceuticals and Crispr Therapeutics go up and down completely randomly.

Pair Corralation between Arrowhead Pharmaceuticals and Crispr Therapeutics

Given the investment horizon of 90 days Arrowhead Pharmaceuticals is expected to generate 1.01 times more return on investment than Crispr Therapeutics. However, Arrowhead Pharmaceuticals is 1.01 times more volatile than Crispr Therapeutics AG. It trades about 0.31 of its potential returns per unit of risk. Crispr Therapeutics AG is currently generating about -0.01 per unit of risk. If you would invest  2,118  in Arrowhead Pharmaceuticals on August 26, 2025 and sell it today you would earn a total of  2,263  from holding Arrowhead Pharmaceuticals or generate 106.85% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Arrowhead Pharmaceuticals  vs.  Crispr Therapeutics AG

 Performance 
       Timeline  
Arrowhead Pharmaceuticals 

Risk-Adjusted Performance

Solid

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Arrowhead Pharmaceuticals are ranked lower than 24 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Arrowhead Pharmaceuticals reported solid returns over the last few months and may actually be approaching a breakup point.
Crispr Therapeutics 

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days Crispr Therapeutics AG has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, Crispr Therapeutics is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors.

Arrowhead Pharmaceuticals and Crispr Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Arrowhead Pharmaceuticals and Crispr Therapeutics

The main advantage of trading using opposite Arrowhead Pharmaceuticals and Crispr Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Arrowhead Pharmaceuticals position performs unexpectedly, Crispr Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crispr Therapeutics will offset losses from the drop in Crispr Therapeutics' long position.
The idea behind Arrowhead Pharmaceuticals and Crispr Therapeutics AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Other Complementary Tools

ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Equity Valuation
Check real value of public entities based on technical and fundamental data